Amedisys Inc (AMED) Shares Bought by AHL Partners LLP

AHL Partners LLP boosted its stake in Amedisys Inc (NASDAQ:AMED) by 333.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 47,994 shares of the health services provider’s stock after buying an additional 36,934 shares during the period. AHL Partners LLP owned approximately 0.14% of Amedisys worth $3,014,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Balyasny Asset Management LLC purchased a new stake in Amedisys in the 2nd quarter valued at about $7,736,000. Numeric Investors LLC purchased a new stake in Amedisys in the 2nd quarter valued at about $339,000. OxFORD Asset Management LLP purchased a new stake in Amedisys in the 2nd quarter valued at about $2,250,000. Dimensional Fund Advisors LP raised its holdings in Amedisys by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,124,943 shares of the health services provider’s stock valued at $70,658,000 after buying an additional 7,963 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in Amedisys by 38.3% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 101,560 shares of the health services provider’s stock valued at $6,379,000 after buying an additional 28,133 shares during the period. Hedge funds and other institutional investors own 96.55% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/11/amedisys-inc-amed-shares-bought-by-ahl-partners-llp.html.

In related news, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now directly owns 10,488 shares in the company, valued at approximately $524,400. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bruce D. Perkins bought 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The shares were bought at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the acquisition, the director now owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. Company insiders own 2.00% of the company’s stock.

Several analysts recently issued reports on the stock. Robert W. Baird restated a “hold” rating and issued a $50.00 price objective on shares of Amedisys in a report on Wednesday, October 4th. BidaskClub lowered shares of Amedisys from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. SunTrust Banks, Inc. restated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Monday. Bank of America Corporation initiated coverage on Amedisys in a research report on Monday, August 21st. They issued a “neutral” rating and a $55.00 target price for the company. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $60.00 target price on shares of Amedisys in a research report on Friday, September 15th. Seven analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $55.90.

Amedisys Inc (NASDAQ AMED) opened at 47.77 on Wednesday. The firm has a market capitalization of $1.62 billion, a P/E ratio of 40.83 and a beta of 0.87. Amedisys Inc has a 52-week low of $34.58 and a 52-week high of $65.91. The firm has a 50-day moving average price of $51.97 and a 200 day moving average price of $55.24.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business posted $0.42 EPS. Analysts

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Balyasny Asset Management LLC purchased a new stake in Amedisys in the 2nd quarter valued at about $7,736,000. Numeric Investors LLC purchased a new stake in Amedisys in the 2nd quarter valued at about $339,000. OxFORD Asset Management LLP purchased a new stake in Amedisys in the 2nd quarter valued at about $2,250,000. Dimensional Fund Advisors LP raised its holdings in Amedisys by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,124,943 shares of the health services provider’s stock valued at $70,658,000 after buying an additional 7,963 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in Amedisys by 38.3% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 101,560 shares of the health services provider’s stock valued at $6,379,000 after buying an additional 28,133 shares during the period. Hedge funds and other institutional investors own 96.55% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/11/amedisys-inc-amed-shares-bought-by-ahl-partners-llp.html.

In related news, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now directly owns 10,488 shares in the company, valued at approximately $524,400. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bruce D. Perkins bought 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The shares were bought at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the acquisition, the director now owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. Company insiders own 2.00% of the company’s stock.

Several analysts recently issued reports on the stock. Robert W. Baird restated a “hold” rating and issued a $50.00 price objective on shares of Amedisys in a report on Wednesday, October 4th. BidaskClub lowered shares of Amedisys from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. SunTrust Banks, Inc. restated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Monday. Bank of America Corporation initiated coverage on Amedisys in a research report on Monday, August 21st. They issued a “neutral” rating and a $55.00 target price for the company. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $60.00 target price on shares of Amedisys in a research report on Friday, September 15th. Seven analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $55.90.

Amedisys Inc (NASDAQ AMED) opened at 47.77 on Wednesday. The firm has a market capitalization of $1.62 billion, a P/E ratio of 40.83 and a beta of 0.87. Amedisys Inc has a 52-week low of $34.58 and a 52-week high of $65.91. The firm has a 50-day moving average price of $51.97 and a 200 day moving average price of $55.24.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business posted $0.42 EPS. Analysts forecast that Amedisys Inc will post $2.21 EPS for the current year.

Amedisys Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply